10:21 AM EDT, 10/11/2024 (MT Newswires) -- Capricor Therapeutics ( CAPR ) on Friday presented positive safety and efficacy data from a three-year extension study for deramiocel, a treatment for cardiomyopathy in patients with Duchenne muscular dystrophy.

The ongoing open-label study found improvement in multiple measures of cardiac function, including left ventricular ejection fraction and indexed volumes, Capricor said.

There was also clear bifurcation in the treatment effect seen in patients with ejection fractions over 45%, suggesting that early and sustained intervention with deramiocel will likely be key to treatment, the company said

Capricor shares were nearly 11% higher in recent trading.

Price: 19.71, Change: +2.57, Percent Change: +14.99